Promising Results from PEGASUS Trial Reported at ACC 2015

Paul Spittle, vice president, Cardiovascular and Respiratory, AstraZeneca US, discusses results from the PEGASUS trial and explains what they may mean for heart attack and stroke risk in patients who have suffered a myocardial infarction.

In one of the most anticipated announcements at the 2015 American College of Cardiology annual meeting in San Diego, researchers presented early promising results from the PEGASUS trial, which compared treatment with ticagrelor and aspirin with aspirin alone.

Paul Spittle, vice president, Cardiovascular and Respiratory, AstraZeneca US, discusses results from the PEGASUS trial and explains what they may mean for heart attack and stroke risk in patients who have suffered a myocardial infarction.